Compare BBSI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | MNKD |
|---|---|---|
| Founded | 1965 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 711.6M | 793.6M |
| IPO Year | 1994 | 2004 |
| Metric | BBSI | MNKD |
|---|---|---|
| Price | $29.16 | $2.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $42.67 | $8.56 |
| AVG Volume (30 Days) | 233.8K | ★ 4.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 5.05 | N/A |
| EPS | ★ 2.08 | 0.02 |
| Revenue | ★ $920,432,000.00 | $348,966,000.00 |
| Revenue This Year | $6.59 | $35.81 |
| Revenue Next Year | $6.05 | $11.89 |
| P/E Ratio | ★ $13.99 | $131.75 |
| Revenue Growth | 9.50 | ★ 22.23 |
| 52 Week Low | $25.33 | $2.23 |
| 52 Week High | $49.65 | $6.51 |
| Indicator | BBSI | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 42.09 |
| Support Level | $28.11 | $2.52 |
| Resistance Level | $29.49 | $6.18 |
| Average True Range (ATR) | 1.05 | 0.12 |
| MACD | 0.13 | 0.11 |
| Stochastic Oscillator | 60.37 | 97.78 |
Barrett Business Services Inc is a provider of payroll administrative services and staffing services. The company categories of services include professional employer services and staffing. Professional employer services offer payroll management, payroll tax services, and workers' compensation coverage solutions, as well as workforce management services, including hiring and termination of employees. Staffing offers temporary staffing services, as well as contract staffing, long-term or indefinite on-site management, and direct placement services. The company operates in the United States of America. It generates maximum revenue from the Professional employer service fees.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.